白细胞介素-2治疗30例肺癌恶性胸腔积液的临床观察

目的　观察重组人白细胞介素- 2 (IL- 2 )胸腔内注射治疗肺癌恶性胸腔积液的疗效及副作用。方法　60例肺癌恶性胸腔积液患者,随机分成二组,每组30例,胸腔微管留置排尽胸水后,治疗组IL- 2 4 0万u,用0 .9%氯化钠注射液2 0ml稀释后注入胸腔治疗;对照组30例,予0 .9%氯化钠注射液2 0ml,顺铂(DDP)按40mg/m2 胸腔内注入。1周1次,每2周为一疗程,观察疗效、近期生存率、机体免疫力及毒副作用。结果　治疗组总有效率80 % ,对照组总有效率50 % ,治疗组较对照组有显著性差异(P <0 .0 5) ;近期生存率方面,0 .5年及1年的近期生存率治疗组有明显提高(P <0 .0 5) ;机体免疫力方面,两组治疗前无明显差别,治疗后,治疗组CD4 /CD8值较对照组明显升高,P <0 .0 1 ) ;副作用方面,除发热外,骨髓抑制、胸痛、消化道症状治疗组较对照组均有显著性差异。结论　IL- 2是治疗肺癌恶性胸腔积液的一种有效的,不良反应小的好方法,并可能提高近期生存率及机体免疫力。

The clinical observation on the treatment of 30 lung cancer patients who has malignant pleural effusions by Interleukin-2

Objective To observe the curative effect and side effect of injecting Interleukin-2 into the thoracic cavity of lung cancer patients who has malignant pleural effusion.Methods Sixty cases were randomly divided into treatment group and control group. For the treatment group, all the pleural effusions were withdrawn and Interleukin-2 400,000 IU was dissolved in saline 20ml and injected into their thoracic cavity. For the control group, cisplatin (40mg/m2) was injected once a week, for a total of 2 weeks. Two weeks later, the curative effects were observed, along with the survival rate, body immunity and side effects. Results The overall effective rate of treatment group was 80% and that of control group was 50% (P<0.05). the 6-month survival rate and one year survival rate for the treatment group was obviously higher than that of the controls (P<0.05). In the evaluation of the body immunity, the value of CD4/CD8 in the treatment group was higher than that of the control group (P<0.01). There was obvious difference between the treatment group and the control group in the degree of bone marrow depression, chest pain and digestive tract symptoms except fever.Conclusion Interleukin-2 is an effective method which has less side effect in the treatment of lung cancer patients who has malignant pleural effusions. It may increase the short-term survival rate and body immunity.